ValuEngine downgraded shares of Calithera Biosciences (NASDAQ:CALA) from a sell rating to a strong sell rating in a research report released on Saturday.

CALA has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of Calithera Biosciences from a buy rating to a hold rating in a research report on Tuesday, January 2nd. BidaskClub downgraded shares of Calithera Biosciences from a sell rating to a strong sell rating in a research report on Saturday, December 9th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of Hold and an average target price of $17.20.

Shares of Calithera Biosciences (NASDAQ CALA) opened at $7.70 on Friday. Calithera Biosciences has a 12-month low of $6.75 and a 12-month high of $20.05. The stock has a market cap of $273.17, a price-to-earnings ratio of -7.78 and a beta of 2.56.

Calithera Biosciences (NASDAQ:CALA) last issued its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. The company had revenue of $7.20 million for the quarter, compared to the consensus estimate of $6.02 million. equities analysts anticipate that Calithera Biosciences will post -0.77 earnings per share for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in CALA. Schwab Charles Investment Management Inc. grew its position in Calithera Biosciences by 249.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 71,600 shares of the biotechnology company’s stock valued at $1,064,000 after purchasing an additional 51,100 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Calithera Biosciences by 230.7% in the second quarter. Bank of New York Mellon Corp now owns 108,102 shares of the biotechnology company’s stock valued at $1,605,000 after acquiring an additional 75,414 shares during the last quarter. Legal & General Group Plc acquired a new stake in Calithera Biosciences in the second quarter valued at $120,000. Wells Fargo & Company MN lifted its stake in Calithera Biosciences by 705.3% in the second quarter. Wells Fargo & Company MN now owns 26,832 shares of the biotechnology company’s stock valued at $399,000 after acquiring an additional 23,500 shares during the last quarter. Finally, Alliancebernstein L.P. acquired a new stake in Calithera Biosciences in the second quarter valued at $899,000. 72.54% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Calithera Biosciences (CALA) Stock Rating Lowered by ValuEngine” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/calithera-biosciences-cala-stock-rating-lowered-by-valuengine/1849213.html.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.